Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study
Authors:
- Alvaro LassalettaALAlvaro Lassaletta
- Katrin ScheinemannKSKatrin Scheinemann
- Shayna M. ZelcerSZShayna M. Zelcer
- Juliette HukinJHJuliette Hukin
- Beverley A. WilsonBWBeverley A. Wilson
- Nada JabadoNJNada Jabado
- Anne Sophie CarretACAnne Sophie Carret
- Lucie Lafay-CousinLLLucie Lafay-Cousin
- Valerie LaroucheVLValerie Larouche
- Cynthia E. HawkinsCHCynthia E. Hawkins
- Gregory Russell PondGPGregory Russell Pond
- Ken PoskittKPKen Poskitt
- 10 October 2016
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (29) , 3537-3543
Abstract
Purpose: Vinblastine monotherapy has shown promising activity and a low-toxicity profile in patients with pediatric low-grade glioma (PLGG) who experienced treatment failure after initial treatment with chemotherapy and/or radiation. The aim of this study was to assess the activity of vinblastine in therapy-naïve children. Patients and Methods: Patients < 18 years old with unresectable and/or progressive therapy-naïve PLGG were eligible. Vinblastine was administered once per week at a dose of 6 mg/m2 intravenously over a period of 70 weeks. Vision, quality of life, neurofibromatosis type 1 (NF1) status, and BRAF mutation/fusion status were also determined and correlated with outcome. Results: Fifty-four patients were enrolled onto the study, with a median age of 8 years (range, 0.7 to 17.2 years). Most patients had chiasmatic/hypothalamic tumors (55.5%), and 13 patients (24.1%) had NF1. The most common histology was pilocytic astrocytoma (46.3%). Seventeen patients were diagnosed using radiologic criteria alone. Best response to chemotherapy was centrally reviewed with a response rate (complete, partial, or minor response) of 25.9%. Disease stabilization (complete, partial, or minor response or stable disease) was achieved in 47 patients (87.0%). Visual improvement was observed in 20% of patients with optic pathway glioma. Five-year overall survival and progression-free survival (PFS) rates were 94.4% (95% CI, 88.5% to 100%) and 53.2% (95% CI, 41.3% to 68.5%), respectively, for the entire cohort. Patients with NF1 had a significantly better PFS (85.1%; 95% CI, 68.0% to 100%) when compared with patients without NF1 (42.0%; 95% CI, 29.1% to 60.7%; P = .012). Age< 3 years or > 10 years was not associated with poor outcome. Treatment was well tolerated, and quality of life was not affected during treatment. In this trial, there was no correlation between BRAF alterations and outcome. Conclusion: Vinblastine administered once per week is well tolerated in children with treatment naïve PLGG. Overall survival and PFS are comparable to current therapies, with a favorable toxicity profile and a maintained quality of life.Keywords
This publication has 22 references indexed in Scilit:
- Advances in the Management of Low-Grade GliomasCurrent Oncology Reports, 2014
- Sustained Response to Weekly Vinblastine in 2 Children With Pilomyxoid Astrocytoma Associated With Diencephalic SyndromeJournal of Pediatric Hematology/Oncology, 2013
- Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and HematologyNeuro-Oncology, 2012
- Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2012
- Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade GliomaJournal of Clinical Oncology, 2012
- The PedsQL™ brain tumor module: Initial reliability and validityPediatric Blood & Cancer, 2006
- Weekly vinblastine in pediatric low‐grade glioma patients with carboplatin allergic reactionCancer, 2005
- Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood.Journal of Clinical Oncology, 1993
- Results of the treatment of children with recurrent gliomas with lomustine and vincristineCancer, 1988
- Response to vincristine of recurrent brain tumors in childrenJournal of Neurosurgery, 1976